By Doug Ahrens, Senior Integrated Offering Manager, Thermo Fisher Scientific, and Mike Pearson, Staff Program Manager, Thermo Fisher Scientific
When preparing to scale up for clinical production, many companies opt to work with multiple CDMOs to ensure supply chain stability. However, managing multiple vendors can take time and focus away from the primary objective – getting the drug ready for trials. This can make it challenging to find a CDMO that meets all of a client’s needs.
In 2018, Kaleido Biosciences took a chance on a single-vendor approach using Thermo Fisher Scientific’s Quick to Care™ program. Kaleido uses differentiated chemistry to produce targeted microbiome treatments. Its complex process and short timeline made for a challenging project, but Thermo Fisher Scientific’s resources ensured a seamless tech transfer and brought the drug to trial participants around the globe on time as promised.